SCHEMBL577432

SCHEMBL577432

O=C(OCCN1C(=O)c2ccccc2C1=O)c1ccccc1O

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.67
GLA P06280 1/20 0.60
BRCA1 P38398 1/20 0.60
TDP1 Q9NUW8 2/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 1/20 0.59
HSD17B10 Q99714 2/20 0.58
PKM P14618 1/20 0.58
GAA P10253 2/20 0.58
TSHR P16473 3/20 0.54
MAPK1 P28482 1/20 0.54
MAPT P10636 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HPGD P15428 1/20 0.53
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 1/20 0.49
APEX1 P27695 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534499 0.85 KMT2A (0.71) SMN1; SMN2TDP1ALDH1A1LMNAHSD17B10
SCHEMBL5536153 0.83 SMN1; SMN2 (0.56) SMN1; SMN2GLABRCA1ALDH1A1LMNA
SCHEMBL6063013 0.79 TDP1 (0.85) SMN1; SMN2GLATDP1ALDH1A1LMNA
SCHEMBL30416074 0.79 TDP1 (0.85) SMN1; SMN2GLATDP1ALDH1A1LMNA
SCHEMBL13685759 0.78 GLA (0.77) SMN1; SMN2GLABRCA1TDP1ALDH1A1
SCHEMBL7712545 0.77 TDP1 (0.65) TDP1ALDH1A1LMNATSHRMEN1
SCHEMBL27989681 0.77 TDP1 (0.65) SMN1; SMN2TDP1ALDH1A1LMNAHSD17B10
SCHEMBL10495293 0.76 SMN1; SMN2 (0.67) SMN1; SMN2GLABRCA1TDP1ALDH1A1
SCHEMBL34474429 0.76 SMN1; SMN2 (0.67) SMN1; SMN2GLABRCA1TDP1ALDH1A1
SCHEMBL28463507 0.76 SMN1; SMN2 (0.67) SMN1; SMN2GLABRCA1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418200-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S. A. (BR) 2012-02-15 EP claimed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, PER2, CRY1 SMN1; SMN2 4021/4885GLA 2637/4885BRCA1 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.